TG Expands Contract With Samsung Biologics to Produce Ublituximab

TG Expands Contract With Samsung Biologics to Produce Ublituximab

293202

TG Expands Contract With Samsung Biologics to Produce Ublituximab

TG Therapeutics has expanded its contract with Samsung Biologics to manufacture ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS). “Samsung is the global leader in biologics manufacturing and we are happy to have them as our partner as we look forward to the potential commercialization of ublituximab across both oncology and autoimmune indications,” Michael S. Weiss, executive chairman and CEO of TG Therapeutics, said in a press release. Ublituximab is an antibody designed…

You must be logged in to read/download the full post.